Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428

Journal of Neuroscience

Volumn 18, Issue 20, 1998, Pages 8417-8422

  McCann, Una D ^a   Wong, Dean F ^b   Yokoi, Fuji ^b   Villemagne, Victor ^b   Dannals, Robert F ^b   Ricaurte, George A ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Amphetamines; Dopamine; Dopamine transporter; Methamphetamine; Neurotoxicity; Parkinsonism

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARBON 11; CATHINONE; DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MALE; NERVE CELL LESION; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; URINALYSIS;

EID: 0032531781     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.18-20-08417.1998     Document Type: Article

References (15)

1. Bakhit C, Morgan MA, Peat MA, Gibb JW (1981) Long-term effects of methamphetamine on the synthesis and metabolism of 5-hydroxytryptamine in various regions of the rat brain. Neuropharmacology 20:1135-1140.
2. Brill H, Hirose T (1969) The rise and fall of a methamphetamine epidemic. Semin Psychiatry 1:179-213.
3. Calkins RF, Aktan GB, Hussain KL (1995) Methcathinone: the next illicit stimulant epidemic? J Psychoact Drugs 27:277-285.
4. Canfield DR, Spealman RD, Kaufman MJ, Madras BK (1990) Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brain. Synapse 6:189-195.
5. Cerruti C, Pillotte N, Uhl G, Kuhar M (1994) Reduction in dopamine transporter mRNA after cessation of repeated cocaine administration. Mol Brain Res 22:1-4.
6. Chappell W, Mordenti J (1991) Extrapolation of toxicological and pharmacological data from animals to humans. In: Advances in drug research (Testa B, ed), pp 1-116. San Diego: Academic.
7. 11C]WIN 35,428). J Labelled Compd Radiopharm 33:147-152.
8. Emerson TS, Cisek JE (1993) Methcathinone: A russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med 22:129-135.
9. Evans AC, Torrescorzo MS, Ku S, Collins L (1991) MRI-PET correlation in three dimensions using a volume-of-interest (VOI) atlas. J Cereb Blood Flow Metab 11:A69-A78.
10. Frey K, Koeppe R, Kilbourn M, Vander Borght T, Albin R, Gilman S, Kuhl D (1996) Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40:873-884.
11. Frey K, Kilbourne M, Robinson T (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334:273-279.
12. 11C-WIN-35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34:423-431.
13. Mordenti J, Chappell W (1989) The use of interspecies scaling in toxicokinetics. In: Toxicokinetics in new drug development (Yacobi A, Kelly J, Batra V, eds), pp 42-96. New York: Pergamon.
14. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235:93-103.
15. Ricaurte GA, Seiden LS, Schuster CR (1984) Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res 303:359-364.